We inferred that the inhibition of tau accumulation and JAK2/STAT1 pathway activation might underlie the common mechanism of CIG’s pharmacological effects on NMDAR expression and synaptic dysfunction in CNS disorders. This evidence concerns the gene JAK2 and central nervous system disorder.